Premium
Pharmacological evaluation of cimetidine, a new histamine H2‐receptor antagonist, in healthy man.
Author(s) -
Burland WL,
Duncan WA,
Hesselbo T,
Mills JG,
Sharpe PC,
Haggie SJ,
Wyllie JH
Publication year - 1975
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1975.tb00564.x
Subject(s) - cimetidine , histamine , histamine h2 receptor , medicine , antagonist , pentagastrin , pepsin , pharmacology , gastric acid , receptor antagonist , endocrinology , secretion , receptor , chemistry , enzyme , biochemistry
Cimetidine, a new H2‐receptor antagonist, was safely administered to eighteen healthy man by the intravenous, intraduodenal or oral route. 2 When gastric secretion was maximally stimulated by either histamine or pentagastrin, the simultaneous administration of cimetidine produced marked inhibition of both acid and pepsin secretion. 3 Cimetidine was well absorbed by mouth and had a blood half‐life of 2 hours. 4 Cimetidine was rapidly excreted via the kidneys and about 70% of the excreted material was unchanged drug. 5 Clinical evaluation of cimetidine in patients with peptic ulceration is recommended.